RxDoctor Payments DataLook up a doctor →

Marja Sprock, MD

Urogynecology and Reconstructive Pelvic Surgery · Rockledge, FLNPI 1336216704

Payments from drug & device makers

$20,912in general payments, 2019–2025

Across 351 payments — averaging $59.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$5K
  • Medtronic$3K
  • AstraZeneca$1K
  • Astellas Pharma US Inc$1K
  • Valencia Technologies Corporation$878
  • Johnson & Johnson$868
  • plus $9K from 49 others

What the payments were for

  • Speaking & faculty fees$4732%
  • Travel & lodging$3,80418%
  • Food & beverage$16,09077%
  • Education$5443%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,912 in reported general payments places this provider in the 80th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

See all urogynecology and reconstructive pelvic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$402,584
Medicare patients
486
Services billed
9,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron91$90,575
GemtesaVibegron83$83,947
Estradiol664$41,390
EstringEstradiol49$25,534
LinzessLinaclotide25$24,097
OsphenaOspemifene37$17,901
Estradiol (Once Weekly)Estradiol90$8,014
ProgesteroneProgesterone, Micronized119$4,328
Estradiol (Twice Weekly)Estradiol31$2,492
Fosfomycin Tromethamine33$1,840
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst147$1,770
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip49$1,189
Clobetasol Propionate24$899
ValacyclovirValacyclovir Hcl21$757
Cefaclor16$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,260$90,57591 claims
Sumitomo Pharma America, Inc.Gemtesa$199$83,94783 claims
PfizerEstring$155$25,53449 claims
AbbVieLinzess$239$24,09725 claims
Duchesnay USA IncorporatedOsphena$151$17,90137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

Other urogynecology and reconstructive pelvic surgery in Rockledge

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →